Welcome to our dedicated page for Quantum-Si news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si stock.
Quantum-Si Incorporated develops proteomics technology for single-molecule protein sequencing and protein analysis. Its updates center on benchtop platform development, real-time kinetic-based detection, and product work around Proteus instruments, the KinetIQ Array and Platinum Pro customer use.
Recurring company news includes quarterly financial results and non-GAAP operating measures, Proteus prototype and integrated-instrument sequencing milestones, amino-acid detection coverage, customer sample testing, scientific posters and manuscripts using Quantum-Si technology, investor conference participation, and equity-inducement grants under Nasdaq rules.
Quantum-Si (Nasdaq: QSI) granted 427,636 restricted stock units (RSUs) to new employees under its 2023 Inducement Equity Incentive Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on June 20, 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to continued employment.
Quantum-Si (Nasdaq: QSI) reported Q1 2026 results and Proteus development progress on May 7, 2026. Q1 revenue was $258,000, gross profit $74,000 and net loss $21.7M. Cash and investments totaled $190.4M, expected to fund operations into Q2 2028. Key technical milestone: automated sequencing on integrated Proteus instruments with a developmental kit detecting 17 amino acids; commercial launch targeted end of 2026.
Quantum-Si (Nasdaq: QSI) will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026. Jeff Hawkins, CEO, and Jeff Keyes, CFO, will hold one-on-one meetings; Hawkins will join a fireside chat at 4:00 PM ET.
A live and archived webcast will be available in the company Investors section under Events & Presentations, and registration is offered for the live stream.
Quantum-Si (Nasdaq: QSI) announced successful sequencing on fully integrated Proteus™ instruments using a developmental KinetIQ™ Array sequencing kit that detects 17 amino acids. The company said the run—from reaction setup to data acquisition—was fully automated without user intervention.
Quantum-Si said this advances detection capabilities from 15 to 17 amino acids since December 2025 and reiterated a goal for Proteus commercial launch by end of 2026, with early access for customers planned this summer and ongoing manufacturing scale-up efforts.
Quantum-Si (Nasdaq: QSI) will report first quarter 2026 financial results on May 7, 2026. A conference call and live webcast with CEO Jeff Hawkins and CFO Jeff Keyes will occur the same day at 4:30 PM ET. An archived webcast will be available after the event.
Investors can listen via the Investors section of the company website or register to receive a dial-in number and personalized PIN to participate.
Quantum-Si (Nasdaq: QSI) announced two customer posters at the American Association of Cancer Research (AACR) annual meeting, April 17-22, 2026 in San Diego.
Poster 2421 (April 20) by Nigel O’Neil, PhD, covers combining deep mutational scanning with benchtop protein sequencing for DNA repair inhibitors. Poster 7650 (April 22) by Gloria Sheynkman, PhD, shows high-resolution PTM detection using single-molecule protein sequencing and its potential to add proteoform characterization to biomarker studies. Management noted ongoing customer pre-prints and momentum toward the planned Proteus launch.
Quantum-Si (Nasdaq: QSI) announced a new manuscript (pre-print, April 14, 2026) showing single-molecule protein sequencing helped identify hybrid human–yeast cohesin complexes relevant to cancer biology. The study used QSI technology to directly demonstrate physical assembly of human and yeast cohesins, a finding that could inform therapeutic discovery.
Quantum-Si (Nasdaq: QSI) granted 61,439 restricted stock units (RSUs) as inducement awards to new employees under its 2023 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on June 20, 2027, with the remainder vesting in 12 equal quarterly installments, subject to continued employment and plan terms.
Quantum-Si (Nasdaq: QSI) completed sequencing of multiple customer samples on a Proteus prototype, testing samples on both Platinum Pro and the Proteus prototype.
According to the company, the Proteus prototype with a developmental sequencing kit delivered improved amino acid coverage, longer read lengths, more peptides identified and greater sequencing output versus Platinum Pro.
Quantum-Si (NASDAQ: QSI) announced a multi-city roadshow to build awareness for its Proteus protein sequencing platform and develop a customer funnel ahead of commercial launch.
First events are in Seattle on April 7, 2026, Washington, D.C. on April 30, 2026, and Houston on May 5, 2026; additional U.S. and European dates will follow.